



# **Parallel Session 2.6**

## **Complex & Innovative Trial Design**

### **– a deep dive into device driven data acquisition**

**Presented by: Nina Christine Reyes Ráfales**  
Manager, Clinical Data Management, IQVIA






# COMPLEX & INNOVATIVE TRIAL DESIGN – A DEEP DIVE INTO DEVICE DRIVEN DATA ACQUISITION

Nina Reyes

March 15, 2022



# Agenda

- + Presenter introduction
- + Device Driven Data Acquisition – what it means
- + Device Driven Data Acquisition – why we need it
- + Device Driven Data Acquisition – best practice
- + Q&A

# Today's Speaker

+ Nina Reyes Ráfales, Manager, Clinical Data Management at IQVIA



+ With a big “THANK YOU” to: Jeff Noll IQVIA Connected Devices, Lead  
For your support

# Devices in Research - what does that mean?



# Data Acquisition than...

*Folders over Folders of patient data in offices full of fireproof filing cabinets containing paper CRF*



Open Slido please and tell me... How can we describe this? *Give me some adverbs! You have 60 seconds.*

# What was next?

*From RDE to EDC*



*Wiki says:*

- An **electronic data capture (EDC)** system is a computerized system designed for the [collection of clinical data](#) in electronic format. EDC replaces the traditional paper-based data collection methodology to streamline data collection and expedite the time to market for drugs and medical devices. EDC solutions are widely adopted by pharmaceutical companies and contract research organizations (CRO).
- EDC is often cited as having its origins in remote data entry (RDE) software, which surfaced in the life sciences market in the late 1980s and early 1990s.

And what an innovation this was back in the 90s!

# And now?

## In the middle of the next evolution: Device Driven Data Acquisition

How can we define this?

The collection of clinical trial data directly from the patient via connected devices / sensors / wearables to reduce dependency on less efficient, more burdensome EDC systems.

But, now let us again interact a bit. Eyes on your devices and open Slido please:

Let's brainstorm → What comes to your mind when you think about Device Driven Data Acquisition?  
**Give me your ideas!**

# Devices in Research - Trends



Increasing Data

All the data generated between the beginning of time and the year 2000, is the same that is now generated every min of every day.<sup>1</sup>



Volume

The body of healthcare data is doubling every 2 years.<sup>2</sup>



EDC Data

Only 20% – 30% of data points collected in EDC



Source Type

By 2020, >200m wearable shipments expected, 1.8m articles published annually<sup>3</sup>



Rising Costs

Processing costs increase exponentially

**Registered clinical trials using connected devices grew more than tenfold<sup>4</sup>, to roughly 1,170 trials in 2018.**

**Forecasts suggest sales will double by 2023<sup>5</sup>.**

1. Marr, Bernard. Why only one of the 5 Vs of big data really matters. 10 March 2015. <http://www.ibmbigdatahub.com/blog/why-only-one-5-vs-big-data-really-matters>

2. European Medicines Agency. Identifying Opportunities for 'Big Data' in medicines development and regulatory science. November 14-15 2016. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Report/2017/02/WC500221938.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/02/WC500221938.pdf)

3. IDC Forecasts Wearables Shipments to Reach 213.6 Million Units Worldwide in 2020 with Watches and Wristbands Driving Volume While Clothing and Eyewear Gain Traction. 15 June 2016. <https://www.idc.com/getdoc.jsp?containerId=prUS41530816>

4. <https://www.nature.com/articles/s41746-020-0259-x/figures/2>

5. <https://www.businesswire.com/news/home/20190516005571/en/World-Market-Connected-Wearables-4th-Edition-Shipments>

# Devices in Research - Trends

## Glucose Monitoring

Beginning in 2015 and increasing steadily 2018-2020 in endocrinology trials, connected glucose meters and continuous glucose monitors have been used to track diabetes patients and their outcomes as well as the impact of experimental drugs on glucose in other therapy areas.

## Blood Pressure

Ambulatory, office and home blood pressure monitors are used across multiple therapy areas to help ensure detection of hypertension or anti-hypertensive effects of drugs, with ABPM showing growth over the past few years. Recent additions are the used of cuffless BP sensors using optical photoplethysmography (PPG) technology and central BP measurement.

## Vitals

The home-based monitoring of SpO2, temperature, heart rate, blood pressure and even respiratory rate through wearable patches and portable devices has grown since 2016 and exploded during the COVID-19 pandemic, especially in infectious disease trials, increasing 22-fold to 11% of all connected devices used in trials.

## Voice/Audio Device Biomarkers

Algorithms built on sensors using sensitive microphones may be used to detect breathing abnormalities, cough type, or pauses in speech that will be increasingly valuable in respiratory, neurology and mental health trials.

## Handheld/Smaller Imaging Devices

New, smaller imaging devices are being created that can be used at the home or by the patient's side, including handheld ultrasounds.

## Ambulatory EEG

Currently used mostly in the clinic or hospital within epilepsy and sleep trials today, ambulatory EEG devices will increasingly be used at home.

## ECGs

The earliest connected device and most used, ECG is employed across therapeutic areas to establish the cardiac safety of investigational medicines, examine their potential for disrupting heart rhythms and to evaluate the wellbeing and safety of subjects.

## Spirometry

A gauge of respiratory health used in respiratory trials and for testing drugs with potential pulmonary toxicity such as in oncology, musculo-skeletal and neurology trials.

## Actigraphy

Actigraphy, which nearly doubled in use since 2019, uses a wrist-worn activity monitor to track movement, sleep and wake patterns over time thereby detecting sleep side effects and physical activity. Originally used for sleep disorder trials, these are now used increasingly in other neurology trials.

## Precision Actigraphy

By tracking nuanced movements, neurodegenerative processes, gait, posture, falls, trembling (seizures) and other symptoms of movement disorders and neurological diseases like Parkinson's (PD) and Alzheimer's can be tracked. In PD, for instance, measures like turning velocity, foot strike angle, arm swing range of motion and first step length<sup>1</sup> may be useful to track severity of disease and patient-related outcomes.

## Facial Imaging Device Digital Biomarkers

Algorithms built on video or image capture devices like smartphones can detect altered facial behavior or emotional expressivity and be used to track subject symptoms within trials such as altered cognitive function or shifts in mental health such as in depression and even detect adverse events in oncology patients.



Source: IQVIA Institute for Human Data Science. Digital Health Trends 2021: Innovation, Evidence, Regulation, Adoption.

Note: Includes devices used for safety as well as efficacy evaluations. 1 MDPI. How to Select Balance Measures Sensitive to Parkinson's Disease from Body-Worn Inertial Sensors – Separating the Trees from the Forest.

Available from: <https://www.mdpi.com/1424-8220/19/15/3320/html>

# Devices in Research // Trial Design – Trends




## Traditional Site-Based



## Hybrid DCT



## Full DCT




# Devices in Research – why we need it!



# Patient Focused Drug Development Trends Drive Demand for Connected Device Solutions



Accelerated patient-centric drug development/data access



- Clinical Sites continue to be the primary source of clinical data in future trials.
- Medical records data is largely inaccessible to the global patient population
- Sites continue to perform most patient recruitment and retention work.


- **Clinical Source data derived both from clinical sites and from the patients themselves, via wearables, in-home care, and ePRO**
- Patients have increasing, yet localized access and decision-making rights to a subset of their medical records data,
- Sites still capture and monitor the majority of source data.
- Patient recruitment and engagement becomes a collaborative effort between sites and CROs.

- **Primary source data for a trial driven by ePRO, wearables, and other patient-centric mechanisms**
- Blockchain and other technologies along with expanded regulation enable secure, patient-mediated medical record exchange.
- Direct to patient is the cornerstone model for clinical trial patient enrollment and retention.

# Better Solutions: Success of complex & innovative designs

*Ability of design to out-perform more traditional design types*

- Ability to make decisions
- Endpoint time to recruitment ratio
- Quickly ingesting data
- Standardized
- Capture as close to source as possible
- High quality data



# Device Driven Data Acquisition: Value Across Development Lifecycle

## Phase I

Connected Devices streams bi-directional, real-time data ensuring **highest level of safety** for patients. Using a high-quality connected Devices Digital Platform enables **seamless data-collection and enhanced study set-up, improving study efficiency.**

## Phase II

Connected Devices provides the opportunity to **collect data from multiple endpoints across all therapeutic areas**, ensuring quality and consistency of data


## Phase III

Connected Devices enables **hybrid and decentralized trials**, providing medically-validated **endpoint data collection to diverse and compromised patient populations** in remote corners of the world

## Phase IV

Connected Devices has multiple patient-centric form factors, enabling **highest level of protocol adherence and reduced deviations, while reducing impacts on quality of life during trial participation.**

# Devices in Research // Impact - Trends





**Devices in Research –  
better devices = better data  
BEST PRACTICE**

# Better Devices // Influencing Selection



## Accessible

---

- Familiar connected devices
- Personal and home devices

## Engaging

---


- Reminders and chat features
- Call center (Help)

## Easy To Use

---

- Clear instructions
- Clean interface
- Multi-lingual

# Better Devices // Qualification of Partners



# Better Data // Source Quality

*Comprehensive eSource strategy leads to a higher quality of data being collected and analyzed*

<h3>Manual Data Entry </h3> <ul style="list-style-type: none"><li>• <b>Up to 30%</b> of data received from sites can contain data entry errors within:<ul style="list-style-type: none"><li>Demographics</li><li>Visit Number/Sequence</li><li>Procedure Results</li></ul></li></ul>	<h3>Poor Data Quality </h3> <ul style="list-style-type: none"><li>• <b>Inexperienced Sites</b> need help to collect quality procedure data that stand alone devices often can't provide.</li></ul>	<h3>Non-Expert Analysis </h3> <ul style="list-style-type: none"><li>• <b>Up to 50%</b> of ECG Machine Measurements don't agree with Cardiologists. Timely expert analysis can be crucial in screening decisions.</li></ul>	<h3>Data Access </h3> <ul style="list-style-type: none"><li>• <b>Less than 50%</b> of devices used on trials in the past had any means to capture users or limit their actions to ensure data integrity.</li></ul>
---	--	---	---

Many of these issues are directly related to the fact that most devices weren't designed for clinical trials.


 Paper-based/manual data collection transcribed into CRFs

 No QC, high query/failure rates

 Source data stored at sites; copies sent for analysis

 Expert analysts often can't help with timely decision making

# Better Devices // Support Services



# Better Devices // Data Driven Selection Methods

Endpoint Strategy, Logistics, Regulatory, Cost

**CONNECTED DEVICES INTELLIGENCE DATABASE**

Home | Device Data | Logistics Data | Reporting | Admin User Setup | Admin Country Setup

**Device Data**

Device	Company	Med Grade Device	Fda Approval	Regional Approval	Age Groups Approval	Primary Endpoint
Biosensor	Philips	Class II	Approved	To be evaluated	18 Years and older	No
Life Sensor Cardiac Monitor	BraveHeart wearable life sensor	Class II	Approved	Currently would be only US and there may...	18 Years and older	No
Everion	Biovotion	Class II	2 Devices available, one is approved and t...	CE Certified	-	No
OPAL	APDM					Uncertain
GT9X Link	Actigraph				18 Years and older	No
ActiGraph CentrePoint Insight Watch	Actigraph				18 Y...	
ActiPa4	ActiPa4				18 Y...	
Band	Activinsights				18 Y...	
Actimyo	I Motion				18 Y...	
AX3	Avivity				18 Y...	
PAM5ys™	Biosensics				18 Y...	
MotionWatch	CamNtech				18 Y...	
MoveMonitor	DynaPort Activity Monit...				18 Y...	
Charge 2	FitBit				18 Y...	
Charge 3	FitBit				18 Y...	
StepWatch	Modus	Class II		To be evaluated		
Alivita Optimized Pedometer	Omron	No		To be evaluated		
ActiCal	Philips	Class II		To be evaluated		
DigiWalker	Yamax DigiWalker	No		To be evaluated		
Verisense	Shimmer	No	No	To be evaluated	18 Y...	
Q-Sense	Medoc	To be determined	No	No		

**Filters**

Enabled Name Type Operator

Id equals Column equals

Column: Id Operator: equals

Id: Device, Company, Med Grade Device, Fda Approval, Regional Approval, Age Groups Approval, Primary Endpoint, Secondary Endpoint, Exploratory Endpoint, Iqvia Qualification Process, Iqvia Readiness, Est Time To Ingest Data, Iqvia Approach Ingest Data, Approx Cost, Therapeutic Areas, Features, Comments, Device Comp, Validated Steps



**CONNECTED DEVICES INTELLIGENCE DATABASE**

Home | Device Data | Logistics Data | Reporting | Admin User Setup | Admin Country Setup

**Reporting**


Select Device: [Dropdown] | Select Country: [Dropdown] | Select TA Indication: [Dropdown]

Search: All Text Columns | Go | Actions

☆ Status, Spreadsheet


Device Name	Country Name	Approval Status	Company	Medical Grade Dev	Iqvia Qualification Process	Iqvia Readiness	Estimated timeline for buil
Ei series 150C	Algeria	Approved	Hillrom	Class I	Qualified	Yes	Currently available
Ei series 150C	Andorra (EU)	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 150C	Argentina	Approved	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 150C	Australia	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 150C	Austria (EU)	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 150C	Bahamas	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 250	Albania	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 250	Algeria	-	Hillrom	Class II	Qualified	Yes	Currently available
Ei series 250	Andorra (EU)	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Argentina	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Australia	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Austria (EU)	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Bahamas	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Bahrian	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Bangladesh	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Belarus	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Belgium	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE
Ei series 250	Bosnia and Herzeg...	-	Hillrom	Class II	Qualified	Yes - 510 K Certified	CE

Country List: Afghanistan, Albania, Algeria, American Samoa (US), American Virgin Islands (US), Andorra (EU), Angola, Anguilla (UK), Antigua/Barbuda, Argentina, Armenia, Aruba (NL), Australia, Austria (EU), Azerbaijan, Bahamas, Bahrian, Bangladesh, Belarus




# Better Data // Ease of Use


*Delivers user-specific benefits across the trial continuum*




# Better Data // Enriched Data



# Better Data // Flexible Ingestion Platform




# Device Data Acquisition Strategy: CDDP eSource Platform



# Better Solutions

A robust solution that meets the new demands of the market



 **100% Data Ingestion Automation**


 **Data-Driven Standardized Process**

 **Real-Time Data Cleaning**

 **Real-Time Flow & Access**

# Better Solutions // Data Ecosystem

The data is what connects us - A single ecosystem for all data-centric activities



# Better Solutions // Increased Data Value



## Reduce risk

Early exploration of doses

---

Comparative analysis versus other compounds

---

Synthetic control arms



## Reduce timelines

Virtual trials

---

Synthetic control arms

---

Master protocols

---

Adaptive designs

**Thanks for your attention  
and enjoy your meal!**

